Anderson DR - Search Results

1

Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.

Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ, Parikh MD. Anderson DR, et al. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4882-4. doi: 10.1016/j.bmcl.2009.02.017. Epub 2009 Feb 8. Bioorg Med Chem Lett. 2009. PMID: 19616942

2

Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).

Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. Anderson DR, et al. J Med Chem. 2007 May 31;50(11):2647-54. doi: 10.1021/jm0611004. Epub 2007 May 5. J Med Chem. 2007. PMID: 17480064

3

Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).

Trujillo JI, Meyers MJ, Anderson DR, Hegde S, Mahoney MW, Vernier WF, Buchler IP, Wu KK, Yang S, Hartmann SJ, Reitz DB. Trujillo JI, et al. Among authors: anderson dr. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4657-63. doi: 10.1016/j.bmcl.2007.05.070. Epub 2007 May 25. Bioorg Med Chem Lett. 2007. PMID: 17570666

4

Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.

Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ. Anderson DR, et al. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4878-81. doi: 10.1016/j.bmcl.2009.02.015. Epub 2009 Feb 8. Bioorg Med Chem Lett. 2009. PMID: 19616945

5

Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.

Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A. Meyers MJ, et al. Among authors: anderson dr. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1543-7. doi: 10.1016/j.bmcl.2010.01.078. Epub 2010 Jan 21. Bioorg Med Chem Lett. 2010. PMID: 20137931

6

A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.

Mourey RJ, Burnette BL, Brustkern SJ, Daniels JS, Hirsch JL, Hood WF, Meyers MJ, Mnich SJ, Pierce BS, Saabye MJ, Schindler JF, South SA, Webb EG, Zhang J, Anderson DR. Mourey RJ, et al. Among authors: anderson dr. J Pharmacol Exp Ther. 2010 Jun;333(3):797-807. doi: 10.1124/jpet.110.166173. Epub 2010 Mar 17. J Pharmacol Exp Ther. 2010. PMID: 20237073

7

Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.

Zapf CW, Gerstenberger BS, Xing L, Limburg DC, Anderson DR, Caspers N, Han S, Aulabaugh A, Kurumbail R, Shakya S, Li X, Spaulding V, Czerwinski RM, Seth N, Medley QG. Zapf CW, et al. Among authors: anderson dr. J Med Chem. 2012 Nov 26;55(22):10047-63. doi: 10.1021/jm301190s. Epub 2012 Nov 12. J Med Chem. 2012. PMID: 23098091

8

Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.

Han S, Czerwinski RM, Caspers NL, Limburg DC, Ding W, Wang H, Ohren JF, Rajamohan F, McLellan TJ, Unwalla R, Choi C, Parikh MD, Seth N, Edmonds J, Phillips C, Shakya S, Li X, Spaulding V, Hughes S, Cook A, Robinson C, Mathias JP, Navratilova I, Medley QG, Anderson DR, Kurumbail RG, Aulabaugh A. Han S, et al. Among authors: anderson dr. Biochem J. 2014 Jun 1;460(2):211-22. doi: 10.1042/BJ20131139. Biochem J. 2014. PMID: 24593284

9

Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).

Anderson DR, Hegde S, Reinhard E, Gomez L, Vernier WF, Lee L, Liu S, Sambandam A, Snider PA, Masih L. Anderson DR, et al. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1587-90. doi: 10.1016/j.bmcl.2005.01.067. Bioorg Med Chem Lett. 2005. PMID: 15745802

10

Aqueous versus non-aqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (MK-2) inhibitor in rats.

Chiang PC, South SA, Daniels JS, Anderson DR, Wene SP, Albin LA, Mourey RJ, Selbo JG. Chiang PC, et al. Among authors: anderson dr. J Pharm Sci. 2009 Jan;98(1):248-56. doi: 10.1002/jps.21425. J Pharm Sci. 2009. PMID: 18449936

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

732 results

Search Page

Filters